Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 10, 2014, Pages

  te Riet, Luuk ^a   van den Heuvel, Mieke ^a   Peutz Kootstra, Carine J ^b   van Esch, Joep H M ^a   van Veghel, Richard ^a   Garrelds, Ingrid M ^a   Musterd Bhaggoe, Usha ^a   Bouhuizen, Angelique M ^a   Leijten, Frank P J ^a   Jan Danser, A H ^a   Batenburg, Wendy W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

(pro)renin receptor blockade; Diabetes; Kidney; Prorenin; Renin inhibition

Indexed keywords

(PRO)RENIN RECEPTOR BLOCKER; ALDOSTERONE; ALISKIREN; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; CREATININE; CYCLOOXYGENASE 2; CYSTATIN C; ENDOTHELIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR BLOCKING AGENT; RENIN; RENIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART; HISTOPATHOLOGY; HYPERKALEMIA; KIDNEY; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC RAT;

(PRO)RENIN RECEPTOR BLOCKADE; DIABETES; KIDNEY; PRORENIN; RENIN INHIBITION;

ALDOSTERONE; AMIDES; ANIMALS; BLOOD PRESSURE; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; FUMARATES; KIDNEY; MALE; OLIGOPEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; STREPTOZOCIN;

EID: 84900807320     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00010.2014     Document Type: Article

References (48)

1. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé CA, Müller DN, Bader M, Nguyen G, Danser AHJ. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 25: 2441-2453, 2007.
2. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN, Danser AHJ. Renin-and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension 58: 1111-1119, 2011.
3. Batenburg WW, van den Heuvel M, van Esch JH, van Veghel R, Garrelds IM, Leijten F, Danser AH. The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats. J Hypertens 31: 292-302, 2013.
4. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145-1147, 1986.
5. Connelly KA, Advani A, Kim S, Advani SL, Zhang M, White KE, Kim YM, Parker C, Thai K, Krum H, Kelly DJ, Gilbert RE. The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens 29: 1175-1184, 2011.
6. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 24: 37-48, 1994.
7. de Boer RA, Azizi M, Danser AH, Nguyen G, Nussberger J, Ruilope LM, Schmieder RE, Volpe M. Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. J Renin Angiotensin Aldosterone Syst 13: 409-412, 2012.
8. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 29: 1240-1251, 1997.
9. Deinum J, Ronn B, Mathiesen E, Derkx FHM, Hop WC, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 42: 1006-1010, 1999.
10. Dong YF, Liu L, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 53: 180-191, 2010.
11. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52: 130-136, 2008.
12. Feldt S, Maschke U, Dechend R, Luft FC, Müller DN. Role of the (pro)renin receptor in transgenic rats with human renin hypertension. J Am Soc Nephrol. In press.
13. Gonzalez AA, Luffman C, Bourgeois CR, Vio CP, Prieto MC. Angiotensin II-independent upregulation of cyclooxygenase-2 by activation of the (pro)renin receptor in rat renal inner medullary cells. Hypertension 61: 443-449, 2013.
14. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
15. Hollenberg NK, Fisher NDL, Nussberger J, Moukarbel GV, Barkoudah E, Danser AHJ. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens 29: 2454-2461, 2011.
16. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (pro)renin receptor expression. Endocrinology 150: 5557-5565, 2009.
17. Huang J, Siragy HM. Regulation of (pro)renin receptor expression by glucose-induced mitogen-activated protein kinase, nuclear factor-B, and activator protein-1 signaling pathways. Endocrinology 151: 3317-3325, 2010.
18. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72: 45-52, 2007.
19. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006.
20. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114: 1128-1135, 2004.
21. Ichihara A, Kaneshiro Y. Response to cardiovascular effects of nonproteolytic activation of prorenin. Hypertension. In press.
22. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T, Nishiyama A, Kawachi H, Shimizu F, Inagami T. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17: 2495-2503, 2006.
23. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47: 894-900, 2006.
24. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17: 1950-1961, 2006.
25. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin ii-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 18: 1789-1795, 2007.
26. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54: 343-352, 1998.
27. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50: 2398-2404, 2007.
28. +-ATPase assembly in murine cardiomyocytes. Circ Res 107: 30-34, 2010.
29. Kobori H, Kamiyama M, Harrison-Bernard LM, Navar LG. Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy. J Investig Med 61: 256-264, 2013.
30. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, Patel K, Ferrario C, Sowers JR. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 150: 2561-2568, 2009.
31. +-ATPase activity in MDCK. C11 collecting duct cells. Am J Physiol Renal Physiol 305: F417-F425, 2013.
32. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 312: 1412-1417, 1985.
33. Mandavia CH, Aroor AR, Demarco VG, Sowers JR. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 92: 601-608, 2013.
34. Maschke U, Muller DN. The (pro)renin receptor and the mystic HRP-is there a role in cardiovascular disease? Front Biosci (Elite Ed) 2: 1250-1253, 2010.
35. Mengel M, Reeve J, Bunnag S, Einecke G, Jhangri GS, Sis B, Famulski K, Guembes-Hidalgo L, Halloran PF. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 9: 1859-1867, 2009.
36. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544, 1990.
37. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
38. Oshima Y, Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Bokuda K, Narita T, Kurosawa H, Sun-Wada GH, Wada Y, Yamada T, Takemoto M, Saleem MA, Quaggin SE, Itoh H. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 22: 2203-2212, 2011.
39. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, Investigators A. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012.
40. Riediger F, Quack I, Qadri F, Hartleben B, Park JK, Potthoff SA, Sohn D, Sihn G, Rousselle A, Fokuhl V, Maschke U, Purfurst B, Schneider W, Rump LC, Luft FC, Dechend R, Bader M, Huber TB, Nguyen G, Muller DN. Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol 22: 2193-2202, 2011.
41. van Damme B, Koudstaal J. Measuring glomerular diameters in tissue sections. Virchows Arch A Pathol Anat Histol 369: 283-291, 1976.
42. van Esch JHM, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AHJ. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 28: 2145-2155, 2010.
43. van Esch JHM, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AHJ. Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats. Hypertension 57: 852-858, 2011.
44. Wegner M, Ganten D, Stasch JP. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats. Hypertens Res 19: 229-238, 1996.
45. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, Johnson MS, Tilmon R, Rehmer N, Ferrario CM, Sowers JR. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 298: F655-F661, 2010.
46. Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension 55: 1454-1460, 2010.
47. Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther 25: 505-515, 2011.
48. Zhang J, Noble NA, Border WA, Owens RT, Huang Y. Receptordependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 295: E810-E819, 2008.